| Friday, 16 April 2004 | ||
| Organisers | W. Kirch (Dresden, Germany) D. Pittrow (Dresden, Germany) |
|
| Sponsors | Sanofi-Synthelabo (Berlin, Germany) (unrestricted educational grant) |
|
Selective Xa inhibitors – further advances in research and therapy |
||
| Friday Morning | ||
| Chairs | W. Kirch (Dresden, Germany) D. Pittrow (Dresden, Germany) |
Abstract number |
| 08.30 – 08.50 | Update on factor Xa inhibition in the treatment of venous thromboembolism H. R. Buller (Amsterdam, The Netherlands) |
134 |
| 08.50 – 09.10 | Fondaparinux as a lead structure for new FXa and thrombin inhibiting antithrombotics S. Alban (Kiel, Germany) |
135 |
| 09.10 – 09.30 | Fondaparinux: an update of new study results R. M. Bauersachs (Darmstadt, Germany) |
136 |
| 09.30 – 09.50 | Idraparinux – characteristics and state of development F. Piovella (Pavia, Italy |
|
| 09.50 – 10.00 | discussion | |
| 10.00 | End of workshop | |
| 10.00 – 11.15 | coffee break + plenary lecture | |
